Age of miracles: A world-first mRNA cancer vaccine has dramatically cut the risk of melanoma recurrence and death in a landmark large-scale trial that signals a new era in personalised cancer medicine. The Australian Prof Georgina Long led Phase 3 trial found that adding a tailor-made cancer vaccine reduced the risk of the recurrence of melanoma or death by 42 per cent, compared with patients who were only given the immunotherapy drug, pembrolizumab (sold as Keytruda). https://www.smh.com.au/national/landmark-moment-sydney-scientists-world-first-cancer-breakthrough-revealed-20261023-p6164q.html